Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The gaming industry is headed for a financial crunch, and Microsoft and others have adopted a winner-take-all strategy.
Following merger discussions two weeks ago, Humana and Cigna are walking away from what would’ve been the largest deal of the year.
“We’re moving away from the black box,” said said Frederick Gertz, founder and CEO of enterprise AI company Collide Technology.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
British American Tobacco shares dropped to a 12-year low after the company announced a $31.5 billion write-down for some of its brands.
StubHub’s latest Year in Live Experiences report found women captivated audiences in 2023 and generated massive ticket sales.
Exxon’s $60 billion planned acquisition of Pioneer Natural Resources has attracted the attention of the Federal Trade Commission.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
Apple will likely face a lot of competition if it decides to get on the road.
After 50 years of performing, world-renowned shock rock group Kiss just played its final show, but the members say the show will go on.
Given that EV batteries are a hot commodity, the tech could help cut costs for fleet operators.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.